Search | Engineering

Subscribe Submit

Home Journals Focus Achievement Fronts About Us 中文版

Resource Type

Journal Article 711

Conference Videos 55

Conference Information 1

Year

2024 5

2023 105

2022 144

2021 143

2020 77

2019 23

2018 19

2017 16

2016 32

2015 20

2014 14

2013 13

2012 26

2011 14

2010 14

2009 25

2008 21

2007 22

2006 3

2005 4

open ︾

Keywords

1 15

Deep learning 7

2 6

Reinforcement learning 5

PD-L1 4

hepatocellular carcinoma 4

1) 3

Multi-agent system 3

3 2

3-propanediol 2

4-Dioxane 2

Active learning 2

Adaptive dynamic programming 2

Anti-inflammation 2

Artificial intelligence 2

Attention mechanism 2

Biodegradation 2

COD 2

Coordination 2

open ︾

Search scope:

排序： Display mode:

Dihydroartemisinin increased the abundance of by YAP1 depression that sensitizes hepatocellular carcinomato anti-PD-1 immunotherapy

Frontiers of Medicine 2023, Volume 17, Issue 4, Pages 729-746 doi: 10.1007/s11684-022-0978-2

Abstract: The effect of anti-programmed cell death 1 (anti-PD-1) immunotherapy is limited in patients with hepatocellularHere, anti-PD-1 treatment decreased A. muciniphila abundance in the colon, but increased YAP1Yap1 knockout enhanced anti-PD-1 efficacy.anti-PD-1 efficacy in liver tumors.anti-PD-1 therapy.

Keywords： hepatocellular carcinoma YAP1 Akkermansia muciniphila anti-PD-1 dihydroartemisinin bile acid

HTML PDF Collect

Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial

Frontiers of Medicine Pages 878-888 doi: 10.1007/s11684-023-0993-y

Abstract: Metastases of uveal melanoma (UM) spread predominantly to the liver. Due to low response rates to systemic therapies, liver-directed therapies (LDT) are commonly used for tumor control. The impact of LDT on the response to systemic treatment is unknown. A total of 182 patients with metastatic UM treated with immune checkpoint blockade (ICB) were included in this analysis. Patients were recruited from prospective skin cancer centers and the German national skin cancer registry (ADOReg) of the German Dermatologic Cooperative Oncology Group (DeCOG). Two cohorts were compared: patients with LDT (cohort A, n = 78) versus those without LDT (cohort B, n = 104). Data were analyzed for response to treatment, progression-free survival (PFS), and overall survival (OS). The median OS was significantly longer in cohort A than in cohort B (20.1 vs. 13.8 months; P = 0.0016) and a trend towards improved PFS was observed for cohort A (3.0 vs. 2.5 months; P = 0.054). The objective response rate to any ICB (16.7% vs. 3.8%, P = 0.0073) and combined ICB (14.1% vs. 4.5%, P = 0.017) was more favorable in cohort A. Our data suggest that the combination of LDT with ICB may be associated with a survival benefit and higher treatment response to ICB in patients with metastatic UM.

Keywords： uveal melanoma liver-directed therapy immune checkpoint blockade SIRT anti-PD-1 anti-CTLA-4

HTML PDF Collect

Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms

Frontiers of Medicine Pages 805-822 doi: 10.1007/s11684-023-1025-7

Abstract: To date, immune checkpoint inhibitors (ICIs) of CTLA-4 and PD-1/PD-L1 represent the main class of immunotherapyBlockade of CTLA-4 and PD-1/PD-L1 has shown remarkable efficacy in several specific types of cancers,the generalized mechanism of targeting cancer metabolism at three crucial immune checkpoints (CTLA-4, PD-1, and PD-L1) to influence ICB therapy and propose potential combined immunotherapeutic strategies co-targeting

Keywords： CTLA-4 PD-1 PD-L1 immune checkpoint blockade (ICB) metabolic reprogramming combined tumor therapeutic

HTML PDF Collect

PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives

Yumeng Wang, Guiling Li

Frontiers of Medicine 2019, Volume 13, Issue 4, Pages 438-450 doi: 10.1007/s11684-018-0674-4

Abstract: Checkpoint blockades targeting the PD-1/PD-L1 axis have achieved effective clinical responses with acceptableIn this review, we summarize recent advances in our understanding of the PD-1/PD-L1 signaling pathway, including the expression patterns of PD-1/PD-L1 and potential PD-1/PD-L1-related therapeutic strategies

Keywords： PD-1 PD-L1 immune checkpoint blockade antibody immunotherapy cervical cancer

HTML PDF Collect

Activation of phagocytosis by immune checkpoint blockade

Chia-Wei Li, Yun-Ju Lai, Jennifer L. Hsu, Mien-Chie Hung

Frontiers of Medicine 2018, Volume 12, Issue 4, Pages 473-480 doi: 10.1007/s11684-018-0657-5

Abstract: On the basis of a recently discovered programmed death protein 1 (PD-1) in TAMs, we discuss the potentialthe corresponding therapies may also stimulate macrophages for phagocytosis and thereby provide extra anti-tumor

Keywords： CD47 PD-1 PD-L1 immunotherapy TAM phagocytosis macrophage

HTML PDF Collect

Molecular classification and precision therapy of cancer: immune checkpoint inhibitors

Yingyan Yu

Frontiers of Medicine 2018, Volume 12, Issue 2, Pages 229-235 doi: 10.1007/s11684-017-0581-0

Abstract: refractory Hodgkin lymphoma, and urothelial carcinoma, all of which carry positive programmed death-1/programmed death-ligand 1 biomarkers.

Keywords： molecular classification precision medicine pembrolizumab PD-1/PD-L1 MSI-H

HTML PDF Collect

High-Affinity Decoy PD-1 Mutant Screened from an Epitope-Specific Cell Library Article

Hao Liu, Chunxia Qiao, Naijing Hu, Zhihong Wang, Jing Wang, Jiannan Feng, Beifen Shen, Yuanfang Ma, Longlong Luo

Engineering 2021, Volume 7, Issue 11, Pages 1557-1565 doi: 10.1016/j.eng.2020.11.011

Abstract:

Immunotherapy with anti-programmed cell death protein-1 (PD-1)/programmed cell death ligandWild-type (WT) PD-1 ectodomain has been shown to have difficulty blocking PD-1/PD-L1 mixture formation-1 binds to PD-L1 or PD-L2.was similar to the effect of the commercial anti-PD-L1 antibody atezolizumab (ATE).-1/PD-L1-related cancers.

Keywords： Decoy PD-1 PD-L1 Mammalian cell library Epitope-oriented

HTML PDF Collect

Synthesis, physicochemical characterizations and catalytic performance of Pd/carbon-zeolite and Pd/carbon-CeO

Zeinab JAMALZADEH, Mohammad HAGHIGHI, Nazli ASGARI

Frontiers of Environmental Science & Engineering 2013, Volume 7, Issue 3, Pages 365-381 doi: 10.1007/s11783-013-0520-5

Abstract: In this work, xylene removal from waste gas streams was investigated via catalytic oxidation over Pd/carbon-zeolite and Pd/carbon-CeO nanocatalysts.

Keywords： Pd/carbon-CeO₂ Pd/carbon-zeolite pine cone ZnCl₂ catalytic oxidation xylene

HTML PDF Collect

Application of StrucGP in medical immunology: site-specific -glycoproteomic analysis of macrophages

Frontiers of Medicine 2023, Volume 17, Issue 2, Pages 304-316 doi: 10.1007/s11684-022-0964-8

Abstract: In this work, we used THP-1-derived macrophages as examples to show the vast potential of a N-bisected GlcNAc, core fucosylated, and sialylated glycans (e.g., HexNAc₄Hex₅Fuc₁Neu5Ac₁, N₄H₅F₁S₁) were increased in M1 andIn addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moietywas detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.

Keywords： macrophage glycoproteome glycopeptides N-glycan structures PD-L1

HTML PDF Collect

Promoting effect of Zr on the catalytic combustion of methane over Pd/γ-Al

Hongbo NA,Tianle ZHU,Zhiming LIU,Yifei SUN

Frontiers of Environmental Science & Engineering 2014, Volume 8, Issue 5, Pages 659-665 doi: 10.1007/s11783-013-0613-1

Abstract: The effect of Zr on the catalytic performance of Pd/γ-Al O for the methane combustion was investigatedThe results show that the addition of Zr can improve the activity and stability of Pd/γ-Al O catalystThe active phase of methane combustion over supported palladium catalyst is the Pd /Pd mixture.Zr addition inhibits Pd aggregation and enhances the redox properties of active phase Pd / Pd .(Pd / Pd ).

Keywords： Pd-Zr/Al₂O₃ methane catalytic combustion catalyst regeneration

HTML PDF Collect

Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy

Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian

Frontiers of Medicine 2019, Volume 13, Issue 1, Pages 32-44 doi: 10.1007/s11684-018-0678-0

Abstract:

Immunotherapy has become the fourth cancer therapy after surgery, chemotherapy, and radiotherapy. In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overall survival rates of patients with refractory cancers, such as advanced melanoma, non-small cell lung cancer, and renal cell carcinoma. However, inhibitor therapies are only effective in a small proportion of patients with problems, such as side effects and high costs. Therefore, doctors urgently need reliable predictive biomarkers for checkpoint inhibitor therapies to choose the optimal therapies. Here, we review the biomarkers that can serve as potential predictors of the outcomes of immune checkpoint inhibitor treatment, including tumor-specific profiles and tumor microenvironment evaluation and other factors.

Keywords： immune checkpoint companion diagnosis PD-L1 tumor mutation burden immune score

HTML PDF Collect

mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

Shi-Yong Sun

Frontiers of Medicine 2021, Volume 15, Issue 2, Pages 221-231 doi: 10.1007/s11684-020-0812-7

Abstract: metabolism, survival, and immune response by forming two important complexes, namely, mTOR complex 1(mTORC1) and complex 2 (mTORC2). mTOR signaling is often dysregulated in cancers and has been consideredmade to develop efficacious mTOR inhibitors, particularly mTOR kinase inhibitors, which suppress mTORC1findings on the essential role of GSK3 in mediating cancer cell response to mTOR inhibitors and mTORC1inhibition-induced upregulation of PD-L1 in cancer cells may provide some explanations.

Keywords： mTOR cancer therapy resistance GSK3 protein degradation E3 ubiquitin ligase PD-L1

HTML PDF Collect

A study on the catalytic performance of Pd/γ-Al

Ruizhi CHU, Xianyong WEI, Zhimin ZONG, Wenjia ZHAO

Frontiers of Chemical Science and Engineering 2010, Volume 4, Issue 4, Pages 452-456 doi: 10.1007/s11705-010-0522-9

Abstract: A series of Pd/γ-Al O hybrid catalysts were prepared by impregnation and subsequent calcination undermicrowave irradiation on the catalytic property was mainly attributed to both the higher dispersion of Pdand the significant increase in the adsorption on the CO-bridge of Pd.CO-bridge adsorption and thereby decreased the catalytic activity, whereas the coverage by metallic Pd

Keywords： Pd/γ-Al₂O₃ direct synthesis dimethyl ether calcination under microwave irradiation

HTML PDF Collect

Selective hydrogenation of acetylene over Pd/CeO

Kai Li, Tengteng Lyu, Junyi He, Ben W. L. Jang

Frontiers of Chemical Science and Engineering 2020, Volume 14, Issue 6, Pages 929-936 doi: 10.1007/s11705-019-1912-2

Abstract: Five hundred ppm Pd/CeO catalyst was prepared and evaluated in selective hydrogenation of acetylenePd/CeO catalyst could be activated by the feed gas during reactions and the catalyst without reductionThis could be ascribed to the formation of Pd Ce O or Pd-O-Ce surface species based on the X-ray diffraction

Keywords： selective hydrogenation acetylene Pd/CeO₂ strong interaction

HTML PDF Collect

QUANTITATIVE STUDY ON ANTI-PEST ACTIVITY OF NATURAL PRODUCTS BASED ON VISUALIZATION FRAMEWORK OF KNOWLEDGE

Frontiers of Agricultural Science and Engineering 2023, Volume 10, Issue 2, Pages 306-332 doi: 10.15302/J-FASE-2023488

Abstract:

● Using visual analysis to predict the trend of natural product pest resistance.

Keywords： anti-pest activity crop protection insect pest natural product visual analysis

HTML PDF Collect

Title Author Date Type Operation

Dihydroartemisinin increased the abundance of by YAP1 depression that sensitizes hepatocellular carcinomato anti-PD-1 immunotherapy

Journal Article

Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial

Journal Article

Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms

Journal Article

PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives

Yumeng Wang, Guiling Li

Journal Article

Activation of phagocytosis by immune checkpoint blockade

Chia-Wei Li, Yun-Ju Lai, Jennifer L. Hsu, Mien-Chie Hung

Journal Article

Molecular classification and precision therapy of cancer: immune checkpoint inhibitors

Yingyan Yu

Journal Article